Arizona Patent of the Month – February 2024

NuvOx Pharma, LLC was founded with a mission of reversing hypoxia. This condition occurs when the body’s cells do not receive enough oxygen and contributes to numerous fatal diseases. In one recent approach, the company has been granted a patent for their fractionated radiotherapy and chemotherapy treatments.

NuvOx Pharma’s invention revolves around a method that combines multi-fraction radiotherapy or chemotherapy with a water emulsion of perfluoropentane, administered to the subject suffering from glioblastoma or a solid hypoxic tumor. This emulsion includes a fluorosurfactant and perfluoropentane, showcasing the precision and innovation embedded in the treatment protocol.

The beauty of this invention lies in its versatility and adaptability. For glioblastoma treatment, the perfluoropentane emulsion is administered concomitantly or up to 120 minutes before each fraction of radiation therapy, coupled with the simultaneous administration of carbogen or supplemental oxygen. The dosage is carefully controlled, ranging from 0.05 cc/kg to 0.3 cc/kg, emphasizing the meticulous nature of NuvOx Pharma’s approach.

Furthermore, the method extends to solid hypoxic tumors, encompassing various types such as pancreatic cancer, non-small cell lung cancer, cervical carcinoma, and more. The flexibility of this treatment is evident in its compatibility with chemotherapeutic agents and immunosensitizing agents, offering a comprehensive approach to combatting diverse forms of cancer.

NuvOx Pharma’s invention is not just a theoretical concept. The practicality and efficacy of the treatment have been demonstrated through rigorous experimentation. The inventive use of Dodecafluoropentane emulsion (DDFPe) has shown promising results in increasing tumor oxygen levels, enhancing the effectiveness of radiation therapy, and ultimately impacting tumor growth.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts